Herborium Group, Inc., is a novel botanical therapeutics' company focused on developing, licensing, and marketing of proprietary, botanical based medicinal products, targeting unmet medical needs.
The Company responds to both consumers and healthcare professionals demand for safe, efficacious, all natural medicinal options for treatment and prevention of selected diseases and health concerns.
excerpt; Herborium Group, Inc., is a novel botanical therapeutics® company focused on developing, licensing, and marketing of proprietary, botanical based medicinal products, targeting unmet medical needs. The Company responds to both consumers and healthcare professionals demand for safe, efficacious, all natural medicinal options for treatment and prevention of selected diseases and health concerns.
The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The potential for this market assesses for over $125 Billon in the USA and UK alone.
This new market is presently positioned for exponential growth since it represents a compelling response to changing needs of a healthcare sector. For the industry, botanical therapeutics provide a value added approach based on product differentiation, higher profit margins, and intellectual property protection with a lower risk and regulatory burden and lower cost. Nutraceuticals (supplements) face increasing FDA and market scrutiny, with massive competitive pressures. To meet the needs of this new growing market opportunity for a diverse spectrum of botanically based drugs, along with complementary and non-traditional therapies, Herborium introduces its own botanical therapeutics® defined as “bridge products”, an emerging category of natural medicines whose safety and efficacy are validated through clinical studies.
Market Data 
Markets 
AI
